Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study.

R Motzer, Manuela Schmidinger, Raymond S. McDermott et al.|Journal of Clinical Oncology|2026

Cited by 4